Representative image
NEW DELHI: Drug firm Zydus Cadila on Thursday said it has received approval from the US health regulator to initiate clinical trials for its drug 'Desidustat' in treatment of chemotherapy-induced anemia (CIA). Desidustat is a novel drug which is also currently undergoing phase-III trials for treating anemia in chronic kidney disease patients and phase-II studies for management of COVID-19 patients.
In a regulatory filing, Zydus Cadila said it has received approval from the US Food and Drug Administration (USFDA) to initiate clinical trials of Desidustat in CIA.
Zydus Cadila Chairman Pankaj R Patel said CIA is a serious unmet medical need and there is a need for novel therapies to address this condition.
"Desidustat has been specifically designed to improve haemoglobin, reduce hepcidin and theRead More – Source
Representative image
NEW DELHI: Drug firm Zydus Cadila on Thursday said it has received approval from the US health regulator to initiate clinical trials for its drug 'Desidustat' in treatment of chemotherapy-induced anemia (CIA). Desidustat is a novel drug which is also currently undergoing phase-III trials for treating anemia in chronic kidney disease patients and phase-II studies for management of COVID-19 patients.
In a regulatory filing, Zydus Cadila said it has received approval from the US Food and Drug Administration (USFDA) to initiate clinical trials of Desidustat in CIA.
Zydus Cadila Chairman Pankaj R Patel said CIA is a serious unmet medical need and there is a need for novel therapies to address this condition.
"Desidustat has been specifically designed to improve haemoglobin, reduce hepcidin and theRead More – Source
